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Abstract 
The purpose of this project was to determine both hepatitis C virus (HCV) screening rates and 
the percentage of cases diagnosed among adults born between 1945 and 1965 in a general 
practice clinic staffed by nurse practitioners (NPs). A descriptive study was conducted using a 
chart review of all patients born between 1945 and 1965 seen by NPs in a primary care clinic 
during a three month period of time. Data was collected on the total number of patients in the 
target group, those born between 1945 and 1965, as well as each patient’s gender, birth date, if 
screened for HCV, result of screening, and the reason for screening. Findings revealed that 
screening rates were suboptimal, with only six out of 178 patients in the target group having 
been screened for HCV. Age and gender did not appear to be a factor in whether or not a patient 
was screened.  
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Practices of Nurse Practitioners in Screening for Hepatitis C 
Statement of the Problem 
 Prevalence. Hepatitis C virus (HCV) causes significant morbidity and mortality in the 
United States (Campos-Outcalt, 2012) and has been declared a global health problem by the 
World Health Organization (WHO) (2012). Approximately 1-1.5% of the U.S. population 
(Campos-Outcalt, 2012) and 3% of the global population (Tran, 2012) are living with a chronic 
HCV infection. It is estimated there are 2.7 million to 3.9 million people in the United States 
chronically infected with HCV (Holmberg, Spradling, Moorman, & Denniston, 2013; Ward, 
Valdiserri, & Koh, 2012). During 2003–2012, the overall average annual rate of newly reported 
HCV infections in Alaska was 133.8 cases per 100,000 population. Rates were highest in the 
Gulf Coast, Anchorage/Mat-Su, and Southeast regions. By rough comparison, in 2011, the rate 
of newly reported HCV in six U.S. states and two large U.S. cities ranged from 36.0 to 239.2 per 
100,000 population (State of Alaska Epidemiology, 2013). Only about one-third of those with 
HCV have been referred for care and 5% to 6% successfully treated (Holmberg et al., 2013). 
From 1999-2007 the number of HCV related deaths increased by 50%.  
 While deaths from HCV have been increasing, the numbers of new infections have 
decreased over the last several decades (it is thought that this is due to new blood safety and 
infection control measures.) The rising morbidity from HCV reflects the changing epidemiology, 
changing incidence, and distribution of the disease. Approximately 81% of those infected were 
born between 1945 and 1965, in a group commonly known as the baby boomer generation. 
Many have been infected for several decades and are now developing cirrhosis and 
hepatocellular carcinoma (Ward, Valdiserri, & Koh, 2012). Overall prevalence may be declining, 
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but the looming increase in mortality among the baby boomer generation is of significant 
concern.  
 Consequences. Unfortunately, from 2000 to 2007, only 4.31% of the population was 
screened for HCV, and among those screened 5.15% were found to be infected (Roblin et al, 
2011). Additionally, in findings from a study presented at the AASLD 2013 annual Liver 
Meeting, it was found that 9.9% of persons born 1945-1965 tested positive for HCV 
(Highleyman, 2013.) Despite recent advances in HCV treatment and care, it is estimated that 
between 50% (Tran, 2012) and 75% (Ward, Valdiserri, & Koh, 2012) of chronically infected 
individuals are unaware of their status because they have never undergone testing. As a 
consequence of these low levels of detection, in combination with the high prevalence of HCV in 
the baby boomer generation, the Centers for Disease Control (CDC) (2012) put forth new 
recommendations regarding screening for HCV (Smith et al., 2012). In addition to screening all 
high risk and symptomatic patients, the CDC now recommends that all adults born between 1945 
and 1965 receive a one-time screening test regardless of risk factors (see Figure 1). This is 
known as birth cohort screening. Additionally, the CDC recommends all persons identified as 
positive for HCV infection undergo a brief alcohol screening with appropriate intervention, 
followed by referral for care and potential treatment of HCV and its associated conditions. These 
recommendations add to, but do not replace, those put forth in 1998 recommending screening for 
high-risk patients (Smith et al., 2012).  
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Persons who should be tested once for HCV include: 
• Adults born 1945 through 1965 
Persons who should be routinely tested for HCV include those who:  
• Are currently injecting drugs 
• Have ever injected drugs 
• Received clotting factor concentrates produced before 1987 
• Were ever on long-term hemodialysis 
• Have persistently abnormal alanine aminotransferance levels (ALT) 
• Were notified they received a blood transfusion from a person who later tested positive 
for HCV infection 
• Received blood, blood components, or organ transplant before July 1992 
• Are infected with HIV 
 
 
Figure 1. CDC Recommendations for HCV screening. (CDC, 2012)  
  
The U.S. Preventive Services Task Force (USPSTF) released a recommendation in June 
2013 that mirrors that of the CDC: screening for those at high risk of infection and a one-time 
screening for those born between 1945 and 1965 (USPFTF, 2013). Previously, the USPSTF 
recommended against testing asymptomatic adults without risk-factors for HCV. Prior to this 
change, Edlin (2012) reported that without a change to recommendations for routine screening, 
HCV-related deaths would quadruple in the next 20 years, and the benefits of birth-cohort 
screening would far outweigh the costs.   
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 Complications of chronic HCV infection include liver failure, liver cancer (hepatocellular 
carcinoma), and death (Holmes, Thompson, & Bell, 2013). HCV is the primary cause of 
cirrhosis and hepatocellular carcinoma globally and the most common cause of liver disease in 
the United States (Lok et al., 2012). It is estimated that 50% of cirrhosis, end-stage liver disease, 
and hepatocellular carcinoma is the result of an HCV infection (Olson & Jacobson, 2011). It is 
also the leading indication for liver transplantation (Lok et al, 2012). About half of those who 
develop cirrhosis will die from liver-related disease. Between 8,000 and 10,000 deaths per year 
in the United States alone are attributed to HCV infection (Missiah, Ostrowski, & Heathcote, 
2008).  
 Primary care includes health promotion, disease prevention, health maintenance, 
counseling, patient education, as well as diagnosis and treatment of acute and chronic illnesses in 
a variety of health care settings (American Academy of Family Physicians, 2013). Primary care 
providers are often the first line of defense in screening for disease, making the primary care 
clinic an ideal setting for HCV screening. Due to their significant role in primary care, nurse 
practitioners (NPs) play a vital role in screening and referral for HCV (Olson & Jacobson, 2011). 
Additionally, the NP is able to evaluate the newly-diagnosed patient by performing liver function 
tests that may reflect advanced liver fibrosis, evaluating immunity to hepatitis A and B, and 
evaluating for fatty liver disease or focal lesions. The NP can also counsel the newly diagnosed 
patient on lifestyle changes (Olson & Jacobson, 2011).  
Purpose 
 The evidence shows that HCV has continued to be a significant health care problem in 
the United States and that new recommendations for birth cohort screening have been 
implemented to reduce morbidity and mortality (Campos-Outcalt, 2012). However, Lugtenberg, 
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Burgers, Besters, Han, and Westert (2011) reported that there is often a gap between guidelines 
and practice. They state that adherence to guidelines is often suboptimal, ranging from 52 to 
95%, depending on which guideline is referenced. Voogdt-Pruis, Van Ree, Gorgels, and 
Beusmans (2011) found that NPs demonstrated higher adherence to guidelines than do other 
general practitioners. They found that 77% of NPs and 57% of general practitioners adhered to 
cardiovascular prevention guidelines. Although the majority of NPs followed the cardiovascular 
guidelines, there is limited evidence of NP adherence specific to HCV screening guidelines. 
However, what is known is that only 4.31% of the total population has been screened for HCV 
(Roblin, Smith, Weinbaum, & Sabin, 2011). In order to reduce the financial and humanitarian 
impact of HCV, it has been shown that interventions are needed to increase screening. However, 
to date, no studies have been conducted regarding whether new birth cohort screening 
recommendations are being implemented and improving screening rates as intended (Hoover et 
al., 2012; Jonckheere, Vincent, Belkhir, Wilmes, Vandercam, & Yombi, 2013). The purpose of 
this project was be to determine both HCV screening rates and the percentage of cases diagnosed 
among adults born between 1945 and 1965 in a general practice clinic staffed by NPs.  
Literature Review 
 Disease Progression. Hepatitis C is an infection with the HCV virus, which results in 
liver inflammation. It is a blood borne illness most often transmitted by sharing needles or other 
equipment to inject drugs (CDC, 2013). Other, less common modes of transmission include 
administration of contaminated blood transfusions, blood products, transplant organs (seen 
before 1992 when HCV blood tests became available), needle stick injuries in health care 
settings, and being born to a mother infected with HCV. HCV cannot be spread through breast 
milk, food or water, saliva, or casual contact such as hugging (WHO, 2013). Tran (2012) stated 
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that when a person initially contracts HCV, there is roughly a 75% chance he/she will become 
chronically infected and a 25% chance his/her immune system will be able to eradicate the virus 
without medical intervention.  
 After exposure, most patients are asymptomatic for several weeks. When initial 
symptoms occur they are mild, nonspecific, intermittent, and may include jaundice, fatigue, 
anorexia, weakness, abdominal pain, and dark urine (Lok et al., 2012). These symptoms may 
appear intermittently for years, but never be severe enough to cause the patient to seek medical 
attention. Missiah, Ostrowski, and Heathcote (2008) stated that eventually fibrosis will develop, 
possibly followed by cirrhosis, hepatocellular carcinoma, and possibly liver-related death. Later 
symptoms are those associated with liver disease, cirrhosis, and hepatocellular carcinoma (Lok et 
al., 2012). 
 Missiha et al. (2008) stated that many patients never develop cirrhosis because of the 
slow progression of HCV. Most sequelae of HCV do not appear until after fibrosis of the liver 
develops into cirrhosis. According to Tran (2012), this often takes 20-30 years. In some 
individuals, the evolution to cirrhosis and eventually end stage liver disease can take up to 50 
years (Missiha et al., 2008). The rate of development is, however, related to several modifiable 
and nonmodifiable factors. Potentially modifiable factors include alcohol consumption, co-
infection with hepatitis B virus or HIV, cigarette smoking, daily cannabis use, and iron overload. 
Nonmodifiable factors include age at infection, duration of infection, male sex, race, genetic 
factors, and viral genotype (Missiha et al, 2008).  
 Testing. According to Campos-Outcalt, (2012) practitioners take a two-step approach to 
screening patients for HCV. First, patients should be tested for HCV antibodies (anti-HCV). If 
that result is positive, then a HCV ribonucleic acid (RNA) and genotype, also called HCV 
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nucleic acid, should be ordered. Depending on how it is ordered, this will provide either a 
quantitative viral load or a qualitative evaluation for presence or absence of the HCV virus. If the 
HCV RNA is negative, then the patient is among the 25% of those who were exposed, but able to 
eradicate the virus without medical intervention. These patients do not need any further testing or 
treatment.  If the nucleic acid test is positive, the patient is chronically infected with HCV. This 
test will also determine with what genotype the patient is infected (see Figure 2).  
 
 
Figure 2. Recommended testing sequence for identifying current HCV infection. (CDC, 2013) 
 
 According to Heck, Dingrando, Proctor, and Cavanagh (2013), HCV antibody tests do 
not distinguish between current and past (resolved) HCV infections. In order to determine 
whether a person is currently infected, an HCV RNA test is needed. Heck et al. (2013) analyzed 
surveillance data reported to the CDC from eight sites in the United States from 2005 to 2011. 
They found that of 217,755 newly reported cases, 49.2% were antibody positive only. These 
HCV Antibody 
test performed 
negative 
no further 
action needed 
positive 
HCV 
RNA/genotype 
test performed 
negative 
no further 
action needed 
positive  
chronically 
infected with 
HCV 
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antibody positive only results were the consequence of past HCV infections that resolved (either 
from treatment or spontaneously), false positive results, or false negative results upon more 
extensive testing. Nucleic acid testing is an improved and more sensitive test for detecting HCV 
RNA. It allows for very small amounts of RNA to be detected by massive copying of the gene 
fragment.   
 Treatment. Campos-Outcalt (2012) state that those who are found to be chronically 
infected with HCV should receive appropriate referral, most often to a gastroenterologist or 
hepatologist, for assessment of possible chronic liver disease and potential treatment. However, 
before they are seen by a specialist, they should be counseled to make lifestyle changes to avoid 
further liver damage, such as stopping or reducing alcohol consumption, avoiding medications or 
herbal substances that can damage the liver, and maintaining a healthy weight. If not already 
immune, vaccines for hepatitis A and hepatitis B virus should be administered as soon as 
possible. They should also be counseled on steps to prevent transmitting HCV to others, such as 
not sharing items that may come into contact with blood (needles, toothbrushes, razors, nail 
clippers) and not donating blood, tissue, or semen. According to Tran (2012), treatment varies 
depending on the HCV viral genotype. HCV is a single-stranded RNA virus that infects liver 
cells. As a consequence of frequent viral mutations, there are more than 50 subtypes, grouped 
into six genotypes.  
 According to Mayhew (2011), HCV is usually treated by a hepatologist or 
gastroenterologist. The goal of treatment is sustained virologic response (SVR) and stopping the 
progression of fibrosis and cirrhosis. A patient has reached SVR when no HCV can be detected 
in his/her blood six months after completing treatment. The risk of hepatocellular carcinoma is 
not eliminated by eradication of HCV; however, it is greatly decreased. Treatment is typically 
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indicated for those who have abnormal alanine aminotransferase values, significant liver fibrosis 
or cirrhosis, normal renal function, are not anemic or neutropenic, and have a willingness to 
comply with therapy. Factors that make treatment less likely to be successful include high viral 
load, obesity, black or Latino race, advanced age, and high degree of liver fibrosis. Grade and 
stage of liver fibrosis is determined by liver biopsy.  
 The treatment for patients with HCV has rapidly changed in recent years. From 1998 to 
2013, therapy evolved from interferon monotherapy, to peginterferon monotherapy, to 
peginterferon plus ribavirin, to triple therapy with peginterferon plus ribavirin plus a NS3A/4A 
protease inhibitor (boceprevir or telaprevir) (University of Washington, 2105). However in 2014, 
three new all-oral regimens were approved by the FDA: (1) ledipasvir-sofosbuvir, (2) simeprevir 
plus sofosbuvir, and (3) ombitasvir, paritaprevir, ritonavir and dasabuvir (AASLD/IDSA/IAS-
USA, 2015). Current guidelines for treatment with these medications are jointly set by the 
American Association for the Study of Liver diseases (AASLD), Infectious Diseases Society of 
America (IDSA), and the International Antiviral Society-USA (IAS-USA.) These new all-oral 
regimens that are safe, highly effective, and require relatively short duration in therapy. In the 
United States, genotype 1 HCV accounts for approximately 70-75% of all HCV infections, 
followed by genotype 2 and 3. Genotype 1 infection has historically been the most difficult to 
treat. However, using the new direct antiviral agents released in 2014, patients with genotype 1 
are now the most likely to have success with treatment, with more than 90% achieving SVR. 
Using current treatment guidelines SVR rates for genotype 2 are approximately 95%, and 65-
80% for genotype 3 (University of Washington, 2015). However, these new treatments have a 
downfall. Complicating the use of these direct acting antiviral agents is the high price of therapy. 
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For example, the cost of the preferred regimens for treatment of genotype 1 infection range from 
approximately $63,000 to $300,000 (University of Washington, 2015).  
 Barriers to screening. Barriers to screening for HCV include lack of provider 
knowledge, cost, and patient resistance. Lugtenberg et al. (2011) report that the greatest barrier to 
screening is patient resistance. Other barriers to screening include limited time of primary care 
visits, awkwardness of discussing behavioral risks, and perceived poor tolerability of HCV 
treatments (Vuppalanchi & Kwo, 2013). Due to frequent, multiple changes in the screening 
recommendations for those born between 1945 and 1965, it is difficult for providers and patients 
to determine whether or not these tests will be covered by private insurance, Medicare, or 
Medicaid. A phone call to Medicaid concerning HCV screening did not result in a clear 
determination of coverage. It was stated that, at this time, services are not authorized and 
coverage is based upon medical necessity and determined at the time of billing. HCV screening 
is not listed under preventive and screening services on the medicare.gov website. However, at 
this time, birth cohort screening is a grade B recommendation by the USPFTF, and therefore 
coverage is mandated, without any cost sharing by the patient, by the Affordable Care Act (The 
AIDS Institute, 2014.) A phone call to Quest Diagnostics Laboratory reveals that the cost of an 
HCV antibody test with reflex, for a patient without insurance, is $139.53.  
 Cost. McGarry et al. (2012) conducted a five year study of the cost effectiveness of 
screening 100% of U.S. residents born between 1946 and 1970, excluding those previously 
diagnosed with HCV. It is interesting to note that the CDC (2012) screening recommendations 
include only screening those born between 1945 and 1965 (Smith et al., 2012). McGarry et al. 
(2012) assumed that all infected patients who meet treatment criteria would be treated. They 
estimated that of the 102 million that would be screened, 1.6 million would have positive results. 
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Screening costs were projected to be higher for birth-cohort screening, costing $80.4 billion 
versus $53.7 billion for risk-based screening. Further, McGarry et al. estimated there would less 
cost associated with the treatment of advanced liver disease because patients would have access 
to early intervention ($31.2 billion vs. $39.8 billion).  
 McGarry et al. (2012) compared birth-cohort screening to risk-based screening and found 
birth cohort screening would lead to 84,000 fewer cases of decompensated liver cirrhosis, 46,000 
fewer cases of hepatocellular carcinoma, 10,000 fewer liver transplants, and 78,000 fewer HCV 
related deaths. The researchers concluded that when looking solely at dollar amounts, birth-
cohort screening was more expensive than risk-based screening. It would cost an estimated 
$37,700 for every year added to a person’s life; however, it was estimated that the average 
consumer would be willing to pay that amount. Screening could therefore be considered cost 
effective.  
 Rein et al. (2012) estimated that nearly 67 million Americans born between 1945 and 
1965 visited a primary care clinic during 2006. Of these, 1.2 million were chronically infected 
but unaware. Almost 15 million of these people underwent antibody testing due to risk factors, 
and of those 135,000 were treated and 53,000 achieved SVR. A much larger number, 60.4 
million people, underwent antibody testing due to birth-cohort screening, and of those 552,000 
people underwent treatment, of those 229,000 achieved SVR. Approximately, 1,070,840 new 
cases were identified due to birth cohort screening. Although birth cohort screening saved an 
estimated 82,000 lives, the monetary cost is high. It is estimated that birth cohort screening, and 
treatment of those found to be infected increased medical costs by $5.5 billion. Additionally, 
productivity loss due to treatment was estimated at $6.9 billion. When looking at the cost per 
year added to a person’s life due to detection and successful treatment of HCV, it is less 
HEPATITIS C   13 
 
expensive when birth cohort screening is used. When compared to risk-based screening, it costs 
an estimated $15,700 less per year of life added.  
 Risks and benefits. The CDC (2012) analyzed both the risks and benefits of birth cohort 
screening prior to releasing recommendations. Benefits include increased focus on preventive 
services, regular medical monitoring, and behavioral changes for those with HCV. Early 
identification increases the likelihood that treatment can be initiated advanced liver disease has 
developed. Risks include potential adverse reactions to treatment medications, screening costs, 
complications associated with liver biopsy (pain, bleeding, intestinal perforation, and death), and 
anxiety associated with a false positive result. However, the benefits appear to outweigh the risks 
and birth cohort screening is expected to reduce HCV related morbidity and mortality (Smith et 
al., 2012). 
 Similar studies. Jonckheere et al. (2013) conducted a retrospective study to determine 
staff knowledge, screening rates, and seroconversion rates for HCV of individuals enrolled in an 
AIDS Reference Centre in order to determine physicians’ adherence to HCV screening 
recommendations. They found that 87.5% of physicians reported adherence to HCV screening 
guidelines (to screen all human immunodeficiency virus (HIV) positive patients); however, in 
2011 it was reported that only 44% of HIV infected individuals had undergone HCV screening. 
This may be explained by a possible response bias in using a self-report measure. When 
reviewing the literature, Jonckheere et al. (2013) found that there was a trend toward low 
adherence to hepatitis screening guidelines. Jonckheere et al. (2013) concluded that there was a 
need for clinics to evaluate their data and implement interventions to increase hepatitis screening, 
including education of clinicians.  
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 Hoover et al. (2012) conducted a retrospective chart review analyzing hepatitis 
prevention in a random sample of HIV-infected men who have had sex with men (MSM) in eight 
HIV clinics in six U.S. cities. Charts were reviewed for evidence of screening for hepatitis A, B, 
and C and vaccination status for hepatitis A and B. They found that screening rates for HCV 
were suboptimal, with only 54% of HIV-infected MSM screening for HCV. Hoover et al. (2012) 
concluded that interventions are needed to increase adherence to guidelines for screening.  
Methods 
 This is a descriptive project designed to determine HCV screening and diagnosis 
rates among those born 1945-1965 seen by NPs in a primary care clinic. Data was collected 
using a chart review of all patients born between 1945 and 1965 seen during a 3-month period of 
time in a primary care clinic of NPs in Anchorage, Alaska. Charts of patients seen by providers 
not currently employed at the clinic were excluded. Data was collected on the total number of 
patients in the target group, those born between1945 and 1965, as well as each patient’s gender, 
birth date, if screened for HCV (yes, no), result of screening (positive, negative, not applicable), 
and the reason for screening (birth-cohort, risk-factor, symptoms, not applicable). A patient was 
considered screened for HCV if there is any record of history of HCV screening. A sample data 
collection sheet is shown in Appendix A.  
 Following the chart review, the educational presentation was offered to the NPs 
employed at the clinic. It included a PowerPoint presentation, which the NPs could review at 
their convenience. It outlined the prevalence of HCV among the target population, the success of 
available treatment options, and the results of the chart review. Additionally, the educational 
PowerPoint recommended that each patient be screened at check in by the front desk staff for 
eligibility for HCV screening. An outline of the PowerPoint presentation is shown in Appendix 
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B. Additionally, a handout was given to the NPs outlining the recommendations released by the 
CDC in 2012 (Smith et al., 2012). A sample handout is shown in Appendix C. Each participant’s 
demographics were compiled in the data collection sheet shown in Appendix A. Participants 
names were not included in this spreadsheet. The original data collection sheets will be held 
confidential in a secure location for 3 years, after which time they will be shredded. 
Data Analysis 
 Data was analyzed using Statistical Package for Social Sciences (SPSS) version 21.0. 
Demographic variables were evaluated using descriptive statistics. Nominal-level variables 
(gender) were analyzed using frequencies. Interval/ratio level data (screening and diagnosis 
rates) are reported as percentages.  
All of the available charts in the clinic were reviewed (n = 178), of which 44.9% (n = 80) 
were male and 55.1% (n = 98) were female. The mean age of the participants was 57.95 years 
(SD = 5.34), with a range of 45 to 70 years. Of the participants in the target group, 3.4% (n = 6) 
had been screened for HCV and 96.6% (n = 172) had not been screened for HCV, represented in 
Figure 3 below.  
 
HEPATITIS C   16 
 
 
                 Figure 3. Percentage of patients 1945-1965 born screened for HCV (n = x). 
 
 Of the six patients screened for HCV, one patient was positive and five were negative for 
HCV. Gender breakdown revealed that three were male and three were female. The average age 
was 56.31 years old (M = 56, SD = 5.53). We were unable to determine the reason why three of 
the patients were screened for HCV. However, we were able to determine that two were screened 
due to a risk factor, and one were screened due to symptoms. No patients were screened due to 
birth cohort. The patient who was screened due to a risk factor was the only patient screened for 
HCV who tested positive.  
Discussion 
 Screening rates for HCV in the target population, those born between 1945 and 1965, 
were suboptimal, with only 3.4% of patients screened. Of the six patients screened, one tested 
positive for HCV. Age and gender do not appear to be a factor in whether or not a patient was 
screened. With no patients screened due to birth cohort, it appears that the CDC (2012) 
guidelines for targeted birth cohort screening were not being followed. While half of the patients 
96.60% 
3.40% 
Not screened Screened
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were screened for unknown reasons, as the reason for screening was not documented in their 
chart, the overall rate of targeted birth cohort screening was subpar. The very low screening rate 
in this pilot study highlights the need for further research. In addition to describing screening and 
diagnosis rate, it would be beneficial to investigate if NPs are aware of the guidelines and the 
reason for non-adherence to CDC (2012) recommendations for HCV screening. Conducting a 
pre-test, post-test exploring whether an educational intervention affects screening rates would 
also be useful. Additionally, in future studies it would be helpful to evaluate screening rates 
among patients seen for preventive care visits.  
 When made aware of the results of HCV screening rates, one NP expressed that she was 
not surprised. She stated she knew that the percentage of patients screened would be low. When 
asked about birth cohort screening in her practice, one NP at the clinic stated that she was aware 
of the recommendations released by the CDC (2012), but that she did not routinely offer her 
patients born from 1945 to 1965 testing. Reasons for not screening were patients without risk 
factors or symptoms were unwilling to accept any risk of being financially responsible for the 
tests when they "knew" they didn't have HCV, and that the clinic performs many Department of 
Transportation physicals, and HCV screening is not required. Additionally, the NP stated that it 
is difficult to include all recommended screening tests given the limited time for routine 
physicals. She usually discusses screening tests for conditions for which a patient is at highest 
risk. There were several limitations of this project. Only one clinic participated in the study and it 
did not accept insurance, which likely reduced the screening rate. This clinic did, however, bill 
Medicaid. Additionally, data was not discriminated based upon the type of visit (preventive care, 
injury, illness, etc.) for which the patient was seen. 
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Outcomes & Implications 
 HCV causes significant morbidity and mortality in the United States. It is estimated that 
up to 1.5% of the US population is living with HCV (Campos-Outcalt, 2012) and that 81% of 
those people were born between 1945 and 1965. Additionally, an estimated 50% to 75% of 
infected individuals have never been screened, and are therefore unaware of their status (Ward, 
Valdiserri, & Koh, 2012.) Recommendations for birth cohort screening were implemented to 
reduce morbidity and mortality (Campos-Outcalt, 2012.) Treatment is available for HCV, but 
can only be offered to those patients who have been tested. Over 90% of patients with HCV 
genotype 1 can achieve SVR, or be “cured” with a twelve week medications, risking minimal 
side effects (University of Washington, 2015). Given recent advancements in treatment, 
screening is especially important now. This project demonstrates that screening for HCV by NPs 
in this study falls far below the national recommendations. By promoting awareness of and 
adherence to HCV screening guidelines, NPs can positively influence outcomes. By routinely 
screening and referring patients with HCV for treatment, NPs can reduce the prevalence of liver 
fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplants (Lok et al., 2012.) Treatment is 
the hands of experts, but the path to cure starts with primary care providers.  
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Appendix A 
Sample Data Collection Sheet 
 Table A-1 
 Collection Sheet for Chart Review 
Patient #: Gender: 
Male (M)/ 
Female 
(F) 
Birth 
date: 
Screened: 
Yes (Y)/ 
No (N) 
Result: 
Positive 
(P)/ 
Negative 
(N)/ Not 
applicable 
(NA) 
Reason screened: 
Birth-cohort 
(BC)/ 
Risk-factor (RF)/ 
Symptoms (SX)/  
Other (O) 
1      
2      
3      
4      
5      
6      
7      
8      
9      
10      
11      
12      
13      
14      
15      
16      
17      
18      
19      
20      
21      
22      
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Appendix B 
Educational PowerPoint Outline 
 Guidelines for Hepatitis C screening in primary care  
 
 the problem 
 
 Hepatitis C virus (HCV) causes significant morbidity and mortality in the United States 
(Campos-Outcalt, 2012) and has been declared a global health problem by the World Health 
Organization (World Health Organization, 2012).  
 prevalence 
 From 1999-2007 the number of HCV related deaths increased by 50%. 
 Although deaths from HCV are increasing, the numbers of new HCV infections have 
decreased over the last several decades. 
 Approximately 81% of those infected were born between 1945 and 1965 (Ward, Valdiserri, 
& Koh, 2012). 
  
 consequences 
 Despite recent advances in HCV treatment and care, it is estimated that only between 50% 
(Tran, 2012) and 75% (Ward, Valdiserri, & Koh, 2012) of chronically infected individuals 
are aware of their status because they have never undergone testing. 
 
 consequences 
 In 2012 the CDC put forth new recommendations stating that in addition to screening all 
high risk and symptomatic patients for HCV, all adults born 1945-1965 receive a one-time 
blood test, regardless of risk factors(Smith et al, 2012).  
 
 consequences 
 Complications of chronic HCV infection include liver failure, liver cancer (hepatocellular 
carcinoma), and death (Holmes, Thompson, & Bell, 2013).  
 Between 8,000 to 10,000 deaths per year in the United States alone are attributed to HCV 
infection (Missiah, Ostrowski and Heathcote, 2008).  
 
 
 Significance to nurse practitioners 
 Due to their significant role in primary care nurse practitioners play a vital role in screening 
and referral for HCV (Olson & Jacobson, 2011).  
 purpose 
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 Due to their significant role in primary care nurse practitioners play a vital role in screening 
and referral for HCV (Olson & Jacobson, 2011).  
 Disease progression 
 
 Hepatitis C is an infection with the HCV virus, which results in liver inflammation.  
 Initial symptoms develop several weeks after exposure and are nonspecific.  
 After several years fibrosis will develop, possibly followed  by cirrhosis, hepatocelluar 
carcinoma, and eventually liver-related death.  
 testing 
 First, patients should be tested for HCV antibodies (anti-HCV). If that result is positive, then 
a HCV nucleic acid test should be ordered.  
 If the nucleic acid test is negative, then the patient was exposed, but is not chronically 
infected.  
 If the nucleic acid test is positive, the patient is chronically infected with HCV.  
 
 treatment 
 Treatment varies depending on the genotype. 
 Genotype 1 is the most common in the U.S. 
 The treatment outlook for patients HCV has rapidly changed in recent years. 
 In 2014 three new all-oral regimens were approved by the Food and Drug Administration 
(FDA) for the treatment of HCV.  
 These new all-oral regimens are more effective and much better tolerated than historical 
treatments.  
 
 
 Treatment efficacy  
 The goal of treatment is sustained virologic response (SVR) and stopping the progression of 
fibrosis and cirrhosis. A patient has reached SVR when no HCV can be detected in their 
blood six months after completing treatment.  
 Multiple recent studies have shown SVR rates greater than 90% for genotype 1, 95% for 
genotype 2, and 65-80% for genotype 3 using current treatment guidelines 
 
 Barriers to screening 
 Barriers to screening for HCV include lack of provider knowledge, cost, and patient 
resistance.  
 Due to frequent, multiple changes in the screening recommendations for those born between 
1945 and 1965 it is difficult to determine whether or not these tests will be covered by 
private insurance, Medicare, or Medicaid.  
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 cost 
 Screening costs are projected higher with birth-cohort screening. 
  It is estimated there would less cost associated with the treatment of advanced liver disease. 
 When looking solely at dollar amounts, birth-cohort screening is more expensive than risk 
based screening. 
 However, birth cohort screening is estimated to save 78,000 lives.  
 Risks and benefits 
 Benefits include increased focus on preventive services, regular medical monitoring, and 
behavioral changes for those with HCV.  
 Risks include potential adverse reactions to treatment medications, screening costs, 
complications associated with liver biopsy (pain, bleeding, intestinal perforation, and death), 
and anxiety associated with a false positive result.  
 Results  
 All of the available charts in the clinic were reviewed (n=178), of which 44.9% were male 
(n=80) and 55.1% were female (n=98). The mean age of the participants was 57.95 years 
(M=57.95, SD=5.34), with a range of 45 to 70 years. Of the participants in the target group, 
3.4% (n=6) had been screened for HCV and 96.6% (n=172) had not been screened for HCV.  
 Who will get this information? 
 The results will be shared with the nurse practitioners who participated in the study.  
 Additionally, the results will be submitted for publication in The Journal for Nurse 
Practitioners. The names of the patients, nurse practitioners, and clinic will be confidential.  
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Appendix C 
HCV Education Handout 
CDC Recommendations for HCV Screening 
Persons who should be tested once for HCV include: 
• Adults born 1945 through 1965 
Persons who should be routinely tested for HCV include those who:  
• Are currently injecting drugs 
• Have ever injected drugs 
• Received clotting factor concentrates produced before 1987 
• Were ever on long-term hemodialysis 
• Have persistently abnormal alanine aminotransference levels (ALT) 
• Were notified they received a blood transfusion from a person who later tested positive 
for HCV infection 
• Received blood, blood components, or organ transplant before July 1992 
• Are infected with HIV 
(CDC, 2013)  
 
 
 
 
